Non-small cell lung cancer · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Vinblastine Variant #01 | — | R 9 253 | 84d | — | 13.7 mo | 3 | R 13 318 PFS proxy | — |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | 5.3 mo | 10.3 mo | 18 | R 18 445 PFS proxy | 32 |
No induction Partial | — | — | — | — | ~31.7 mo | — | — | 5 |
3 of 3 regimens shown